Actively Recruiting
International Registry Study to Assess Long-term Safety and Effectiveness of Palovarotene in Fibrodysplasia Ossificans Progressiva FOP
Led by Ipsen · Updated on 2026-10-23
100
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to collect and analyze long-term safety and effectiveness data for palovarotene in people with fibrodysplasia ossificans progressiva FOP, a very rare and disabling condition characterized by abnormal bone growth in soft tissues. Participants include children and adults, some already treated with palovarotene and others untreated. The study will compare safety outcomes and effectiveness between these groups in real-world settings. Participants will either continue receiving palovarotene as prescribed by their doctors or remain untreated with this medication. The study will observe these two groups over time, documenting flare-ups, growth, bone fractures, and physical function. Data collection will include information on daily activities and physical performance related to FOP and palovarotene treatment. During the study, participants will have assessments such as joint involvement scales, lung function tests, physical function questionnaires, and reports on flare-ups and fractures. These evaluations will occur at baseline and regularly up to eleven years. Safety monitoring includes treatment-emergent adverse events and pregnancy outcomes, with follow-up on babies born to participants. Overall, the study follows participants from baseline up to 11 years, providing comprehensive long-term data.
CONDITIONS
Brief Title
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Research Team
I
Ipsen Clinical Study Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here